Investigation into the cardiotoxic effects of doxorubicin on contractile function and the protection afforded by cyclosporin A using the work-loop assay

Toxicology in Vitro

Volumn 28, Issue 5, 2014, Pages 722-731

  Gharanei, Mayel ^a   Hussain, Afthab ^a   James, Rob S ^a   Janneh, Omar ^b   Maddock, Helen ^a  

^a Faculty of Engineering and Computing   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cardiotoxicity; CsA; Doxorubicin; Force; MPTP

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; CARDIOTOXIN; CYCLOSPORIN;

ANIMAL TISSUE; ARTICLE; ASSAY; CARDIOTOXICITY; CONTROLLED STUDY; HEART CONTRACTION; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART PROTECTION; IN VITRO STUDY; MALE; NONHUMAN; PRESSURE VOLUME CURVE; RAT; WORK LOOP ASSAY; ANIMAL; BIOASSAY; DRUG EFFECTS; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL ASSAY; CARDIOTONIC AGENTS; CARDIOTOXINS; CYCLOSPORINE; DOXORUBICIN; IN VITRO TECHNIQUES; MALE; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; RATS, SPRAGUE-DAWLEY;

EID: 84897946672     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.01.011     Document Type: Article

References (62)

1. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol. 1992, 19:529-542.
2. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., Nagai R. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell. Cardiol. 1998, 30:243-254.
3. Arai M., Yoguchi A., Takizawa T., Yokoyama T., Kanda T., Kurabayashi M., Nagai R. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ. Res. 2000, 86:8-14.
4. Boucek R.J., Dodd D.A., Atkinson J.B., Oquist N., Olson R.D. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 1997, 29:2631-2640.
5. Caiozzo V.J. Plasticity of skeletal muscle phenotype: mechanical consequences. Muscle Nerve 2002, 26:740-768.
6. Carafoli E. The homeostasis of calcium in heart cells. J. Mol. Cell. Cardiol. 1985, 17:203-212.
7. Crompton M., Virji S., Doyle V., Johnson N., Ward J.M. The mitochondrial permeability transition pore. Biochem. Soc. Symp. 1999, 66:167-179.
8. de Beer E.L., Bottone A.E., van Der Velden J., Voest E.E. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol. Pharmacol. 2000, 57:1152-1157.
9. 2+, intercellular electrical coupling, and mechanical activity in ischemic rabbit papillary muscle. Effects of preconditioning and metabolic blockade. Circ. Res. 1996, 79:237-246.
10. Delhaas T., Arts T., Bovendeerd P.H., Prinzen F.W., Reneman R.S. Subepicardial fiber strain and stress as related to left ventricular pressure and volume. Am. J. Physiol. 1993, 264:H1548-H1559.
11. Delhaas T., Arts T., Prinzen F.W., Reneman R.S. Relation between regional electrical activation time and subepicardial fiber strain in the canine left ventricle. Pflugers Arch. 1993, 423:78-87.
12. Dodd D.A., Atkinson J.B., Olson R.D., Buck S., Cusack B.J., Fleischer S., Boucek R.J. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest. 1993, 91:1697-1705.
13. Force T., Kerkela R. Cardiotoxicity of the new cancer therapeutics-mechanisms of, and approaches to, the problem. Drug Discov. Today 2008, 13:778-784.
14. Gharanei M., Hussain A., Janneh O., Maddock H.L. Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicol. Appl. Pharmacol. 2012.
15. Gharanei M., Hussain A., Janneh O., Maddock H.L. Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore. Toxicol. Appl. Pharmacol. 2013, 268:149-156.
16. Griffiths E.J., Halestrap A.P. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. Biochem. J. 1991, 274(Pt 2):611-614.
17. Griffiths E.J., Halestrap A.P. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J. Mol. Cell. Cardiol. 1993, 25:1461-1469.
18. Halestrap A.P. What is the mitochondrial permeability transition pore?. J. Mol. Cell. Cardiol. 2009, 46:821-831.
19. Halestrap A.P., Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim. Biophys. Acta 2009, 1787:1402-1415.
20. Halestrap A.P., Connern C.P., Griffiths E.J., Kerr P.M. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol. Cell Biochem. 1997, 174:167-172.
21. Hausenloy D.J., Maddock H.L., Baxter G.F., Yellon D.M. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc. Res. 2002, 55:534-543.
22. Hausenloy D.J., Lim S.Y., Ong S.G., Davidson S.M., Yellon D.M. Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning. Cardiovasc. Res. 2010, 88:67-74.
23. Hirakawa S., Sasayama S., Tomoike H., Crozatier B., Franklin D., McKown D., Ross J. In situ measurement of papillary muscle dynamics in the dog left ventricle. Am. J. Physiol. 1977, 233:H384-H391.
24. James R.S., Young I.S., Cox V.M., Goldspink D.F., Altringham J.D. Isometric and isotonic muscle properties as determinants of work loop power output. Pflugers Arch. 1996, 432:767-774.
25. Janssen P.M., Zeitz O., Keweloh B., Siegel U., Maier L.S., Barckhausen P., Pieske B., Prestle J., Lehnart S.E., Hasenfuss G. Influence of cyclosporine A on contractile function, calcium handling, and energetics in isolated human and rabbit myocardium. Cardiovasc. Res. 2000, 47:99-107.
26. Josephson R.K. Mechanical power output from striated muscle during cyclic contraction. J. Exp. Biol. 1985, 493-512.
27. Josephson R.K. Contraction dynamics and power output of skeletal muscle. Annu. Rev. Physiol. 1993, 55:527-546.
28. Katz A.M., Katz P.B. Homogeneity out of heterogeneity. Circulation 1989, 79:712-717.
29. Kawano K., Kim Y.I., Kaketani K., Kobayashi M. The beneficial effect of cyclosporine on liver ischemia in rats. Transplantation 1989, 48:759-764.
30. Layland J., Kentish J.C. Positive force- and [Ca2+]i-frequency relationships in rat ventricular trabeculae at physiological frequencies. Am. J. Physiol. 1999, 276:H9-H18.
31. Layland J., Kentish J.C. Effects of 1- or -adrenoceptor stimulation on work-loop and isometric contractions of isolated rat cardiac trabeculae. J. Physiol. 2000, 524(Pt 1):205-219.
32. Layland J., Young I.S., Altringham J.D. The effect of cycle frequency on the power output of rat papillary muscles in vitro. J. Exp. Biol. 1995, 198:1035-1043.
33. Layland J., Young I.S., Altringham J.D. The length dependence of work production in rat papillary muscles in vitro. J. Exp. Biol. 1995, 198:2491-2499.
34. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., Heide R.V. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1273-H1280.
35. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
36. Liu J., Mao W., Ding B., Liang C.S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1956-H1965.
37. Marechal X., Montaigne D., Marciniak C., Marchetti P., Hassoun S.M., Beauvillain J.C., Lancel S., Neviere R. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clin. Sci. (Lond.) 2011, 121:405-413.
38. Méndez J., Keys A. Density and composition of mammalian muscle. Metabolism 1960, 9:184-188.
39. Min J.Y., Hampton T.G., Wang J.F., DeAngelis J., Morgan J.P. Depressed tolerance to fluorocarbon-simulated ischemia in failing myocardium due to impaired [Ca(2+)](i) modulation. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1446-H1456.
40. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
41. Montaigne D., Marechal X., Baccouch R., Modine T., Preau S., Zannis K., Marchetti P., Lancel S., Neviere R. Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicol. Appl. Pharmacol. 2010, 244:300-307.
42. Montaigne D., Marechal X., Preau S., Baccouch R., Modine T., Fayad G., Lancel S., Neviere R. Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 2011, 11:22-26.
43. Morin D., Assaly R., Paradis S., Berdeaux A. Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr. Med. Chem. 2009, 16:4382-4398.
44. Mudalagiri N.R., Mocanu M.M., Di Salvo C., Kolvekar S., Hayward M., Yap J., Keogh B., Yellon D.M. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br. J. Pharmacol. 2008, 153:50-56.
45. Olson R.D., Mushlin P.S., Brenner D.E., Fleischer S., Cusack B.J., Chang B.K., Boucek R.J. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA 1988, 85:3585-3589.
46. Olson R.D., Gambliel H.A., Vestal R.E., Shadle S.E., Charlier H.A., Cusack B.J. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc. Toxicol. 2005, 5:269-283.
47. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., Elbelghiti R., Cung T.T., Bonnefoy E., Angoulvant D., Macia C., Raczka F., Sportouch C., Gahide G., Finet G., Andre-Fouet X., Revel D., Kirkorian G., Monassier J.P., Derumeaux G., Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New Engl. J. Med. 2008, 359:473-481.
48. Semafuko W.E., Bowie W.C. Papillary muscle dynamics: in situ function and responses of the papillary muscle. Am. J. Physiol. 1975, 228:1800-1807.
49. Shiga Y., Onodera H., Matsuo Y., Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res. 1992, 595:145-148.
50. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl. J. Med. 1998, 339:900-905.
51. Sivaraman V., Mudalagiri N.R., Di Salvo C., Kolvekar S., Hayward M., Yap J., Keogh B., Hausenloy D.J., Yellon D.M. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res. Cardiol. 2007, 102:453-459.
52. Sperelakis N. Heart Physiology and Pathophysiology 2001, Academic Press, San Diego, California. fourth ed.
53. Stehle R., Iorga B. Kinetics of cardiac sarcomeric processes and rate-limiting steps in contraction and relaxation. J. Mol. Cell. Cardiol. 2010, 48:843-850.
54. Syme D.A., Josephson R.K. Influence of muscle length on work from trabecular muscle of frog atrium and ventricle. J. Exp. Biol. 1995, 198:2221-2227.
55. 2+ and oxidant stress. Eur. J. Biochem. 1996, 238:166-172.
56. Vinnakota K.C., Bassingthwaighte J.B. Myocardial density and composition: a basis for calculating intracellular metabolite concentrations. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1742-H1749.
57. Wang Y.X., Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ. Res. 1995, 76:645-653.
58. Wang G.X., Wang Y.X., Zhou X.B., Korth M. Effects of doxorubicinol on excitation-contraction coupling in guinea pig ventricular myocytes. Eur. J. Pharmacol. 2001, 423:99-107.
59. Yang C.W., Ahn H.J., Han H.J., Kim W.Y., Li C., Shin M.J., Kim S.K., Park J.H., Kim Y.S., Moon I.S., Bang B.K. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. Transplantation 2001, 72:1753-1759.
60. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. New Engl. J. Med. 2007, 357:1121-1135.
61. Zhang Y.W., Shi J., Li Y.J., Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp. (Warsz) 2009, 57:435-445.
62. Zimmer H.G. Who discovered the Frank-Starling mechanism?. News Physiol. Sci. 2002, 17:181-184.